Skip to main content
SpringerLink
Log in

Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients

  • Pharmacokinetics and Disposition
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To establish the population pharmacokinetic (PPK) model of cyclosporine (CsA) in Chinese renal transplant recipients and evaluate the influence of various indexes including CYP3A5 and MDR1 genetic polymorphism on pharmacokinetic parameters.

Methods

Trough (C0) and peak (C2) CsA concentration were monitored conventionally after renal transplantation. C0 and C2 were collected for 5 months in 146 patients. The CYP3A5*3 genotype and MDR1 haplotype were determined by methods based on amplification refractory mutant PCR. The data were analyzed by nonlinear mixed-effect modeling (NONMEM). The model was evaluated using goodness of fit plots and relative error measurements. Physiological and pathological factors including CYP3A5 and MDR1 genotypes were evaluated as covariates of CsA pharmacokinetic parameters.

Results

Pharmacokinetics of CsA was best described by a one-compartment disposition model followed a first-order absorption process. The estimated clearance (CL/F) was 49.5 l·h−1, the volume of distribution (Vd/F) was 226 l. Ka was fixed as 1.25 h−1. Post-transplant data, body weight, total bilirubin, and MDR1 genotype were covariates of CL/F (P < 0.005). Gender and MDR1 haplotype were covariates of Vd/F (P < 0.005). The AUC estimated based on the Bayesian method was 7,465 ± 1,708 ng·h·ml−1 (2,946 ∼13,926 ng·h·ml-1).

Conclusion

The PPK model developed in this study could be used to optimize CsA dose for Chinese renal transplant recipients by using conventional therapeutic drug monitoring (TDM) data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. The Canadian Multicentre Transplant Study Group (1986) A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. N Engl J Med 314(19):1219–1225

    Article  Google Scholar 

  2. Ponticelli C, Minetti L, Di Palo FQ, Vegeto A, Belli L, Corbetta G, Tarantino A, Civati G (1988) The Milan clinical trial with cyclosporine in cadaveric renal transplantation. A three year follow up. Transplantation 45(5):908–913

    Article  PubMed  CAS  Google Scholar 

  3. Kahan BD (2004) Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 36(2 Suppl):378S–391S

    Article  PubMed  CAS  Google Scholar 

  4. Nankivell BJ, Hibbins M, Chapman JR (1994) Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation 58(9):989–996

    Article  PubMed  CAS  Google Scholar 

  5. Oellerich M, Armstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R, Lindholm A, Halloran P, Gallicano K, Wonigeit K (1995) Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 17(6):642–654

    Article  PubMed  CAS  Google Scholar 

  6. Lindholm A, Kahan BD (1993) Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 54(2):205–218

    Article  PubMed  CAS  Google Scholar 

  7. Schroeder TJ, Hariharan S, First MR (1994) Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients. Transplant Proc 26(5):2787–2790

    PubMed  CAS  Google Scholar 

  8. Kahan BD, Grevel J (1988) Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 46(5):631–644

    Article  PubMed  CAS  Google Scholar 

  9. International Neoral Renal Transplantation Study Group (2002) Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2(2):148–156

    Article  Google Scholar 

  10. Lindholm A, Säwe J (1995) Pharmacokinetics and therapeutic drug monitoring of immunosuppressants. Ther Drug Monit 17(6):570–573

    Article  PubMed  CAS  Google Scholar 

  11. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P (1998) Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 66(12):1621–1627

    Article  PubMed  CAS  Google Scholar 

  12. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH (2002) Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 24(4):479–486

    Article  PubMed  CAS  Google Scholar 

  13. Marquet P (2005) Clinical application of population pharmacokinetic methods developed for immunosuppressive drugs. Ther Drug Monit 27(6):727–732

    Article  PubMed  Google Scholar 

  14. Awni WM (1992) Pharmacodynamic monitoring of cyclosporin. Clin Pharmacokinet 23(6):428–448

    Article  PubMed  CAS  Google Scholar 

  15. Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, Bernard N, Thiry P, Le Meur Y, Rousseau A (2006) Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet 45(9):905–922

    Article  PubMed  CAS  Google Scholar 

  16. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA (1992) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Biochem Pharmacol 43(10):2201–2208

    Article  Google Scholar 

  17. Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, Huang JD (2001) Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29(3):268–273

    PubMed  CAS  Google Scholar 

  18. Balram C, Zhou Q, Cheung YB, Lee EJ (2003) CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 59(2):123–126

    PubMed  CAS  Google Scholar 

  19. Miao LY, Huang CR, Hou JQ, Qian MY (2008) Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 29(1):1–5

    Article  PubMed  CAS  Google Scholar 

  20. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22(47):7468–7485

    Article  PubMed  CAS  Google Scholar 

  21. Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13–33

    Article  PubMed  CAS  Google Scholar 

  22. Sakaeda T, Nakamura T, Okumura K (2002) MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 25:1391–1400

    Article  PubMed  CAS  Google Scholar 

  23. Chen B, Zhang W, Fang J, Jin Z, Li J, Yu Z, Cai W (2009) Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients. Xenobiotica 39(12):931–938

    Article  PubMed  CAS  Google Scholar 

  24. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nepharon 16:31–41

    Article  CAS  Google Scholar 

  25. Traub SL, Johnson CE (1980) Comparison of methods of estimating creatinine clearance in children. Am J Hosp Pharm 37:195–201

    PubMed  CAS  Google Scholar 

  26. Chen B, Fang J, Zhang W, Jin Z, Yu Z, Cai W (2009) Detection of C1236T, G2677T/A, and C3435T polymorphism of MDR1 by amplification refractory mutation system PCR. J Clin Lab Anal 23(2):110–116

    Article  PubMed  CAS  Google Scholar 

  27. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263–265

    Article  PubMed  CAS  Google Scholar 

  28. Wu KH, Cui YM, Guo JF, Zhou Y, Zhai SD, Cui FD, Lu W (2005) Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos 33(9):1268–1275

    Article  PubMed  CAS  Google Scholar 

  29. Schädeli F, Marti HP, Frey FJ, Uehlinger DE (2002) Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients. Clin Pharmacokinet 41(1):59–69

    Article  PubMed  Google Scholar 

  30. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ (2003) Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13(2):89–95

    Article  PubMed  CAS  Google Scholar 

  31. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG (2002) Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12:425–427

    Article  Google Scholar 

  32. Keown P, Landsberg D, Halloran P, Shoker A, Rush D, Jeffery J, Russell D, Stiller C, Muirhead N, Cole E, Paul L, Zaltzman J, Loertscher R, Daloze P, Dandavino R, Boucher A, Handa P, Lawen J, Belitsky P, Parfrey P (1996) A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 62(12):1744–1752

    Article  PubMed  CAS  Google Scholar 

  33. David OJ, Johnston A (2001) Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit 23(2):100–114

    Article  PubMed  CAS  Google Scholar 

  34. Rosenbaum SE, Baheti G, Trull AK, Akhlaghi F (2005) Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit 27(2):116–122

    Article  PubMed  CAS  Google Scholar 

  35. Fanta S, Jönsson S, Backman JT, Karlsson MO, Hoppu K (2007) Developmental pharmacokinetics of ciclosporin—a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol 64(6):772–784

    PubMed  CAS  Google Scholar 

  36. Grevel J, Post BK, Kahan BD (1993) Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients. Clin Pharmacol Ther 53(6):651–660

    Article  PubMed  CAS  Google Scholar 

  37. Parke J, Charles BG (2000) Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model. Eur J Clin Pharmacol 56(6–7):481–487

    Article  PubMed  CAS  Google Scholar 

  38. Irtan S, Saint-Marcoux F, Rousseau A, Zhang D, Leroy V, Marquet P, Jacqz-Aigrain E (2007) Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit 29(1):96–102

    Article  PubMed  CAS  Google Scholar 

  39. Lampen A, Christians U, Bader A, Hackbarth I, Sewing KF (1996) Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology 52(3):159–168

    Article  PubMed  CAS  Google Scholar 

  40. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22(6):947–955

    PubMed  CAS  Google Scholar 

  41. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmöller J, Halpert JR, Zanger UM, Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773–779

    Article  PubMed  CAS  Google Scholar 

  42. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391

    Article  PubMed  CAS  Google Scholar 

  43. Min DI, Ellingrod VL, Marsh S, McLeod H (2004) CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 26(5):524–528

    Article  PubMed  CAS  Google Scholar 

  44. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14(3):147–154

    Article  PubMed  CAS  Google Scholar 

  45. Fredericks S, Jorga A, MacPhee IA, Reboux S, Shiferaw E, Moreton M, Carter ND, Holt DW, Johnston A (2007) Multi-drug resistance gene-1 (MDR1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clin Transplant 21(2):252–257

    Article  PubMed  Google Scholar 

  46. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735–7738

    Article  PubMed  CAS  Google Scholar 

  47. Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55(1):3–29

    Article  PubMed  CAS  Google Scholar 

  48. Christians U, Sewing KF (1993) Cyclosporin metabolism in transplant patients. Pharmacol Ther 57(2–3):291–345

    Article  PubMed  CAS  Google Scholar 

  49. Lindholm A (1991) Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 13:464–477

    Article  Google Scholar 

Download references

Acknowledgement

Supported by the National Natural Science Foundation of China (No. 30500626).

Author information

Authors and Affiliations

  1. Department of Pharmacy, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, People’s Republic of China

    Bing Chen, WeiXia Zhang, Juan Li & YuXin Zhang

  2. Department of Medical Laboratory, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, People’s Republic of China

    ZhiDong Gu

  3. Department of Clinical Pharmacy, Fudan University, School of Pharmacy, Shanghai, 201203, People’s Republic of China

    WeiMin Cai

Authors
  1. Bing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. WeiXia Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. ZhiDong Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Juan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. YuXin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. WeiMin Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to WeiMin Cai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, B., Zhang, W., Gu, Z. et al. Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. Eur J Clin Pharmacol 67, 601–612 (2011). https://doi.org/10.1007/s00228-010-0959-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-010-0959-2

Keywords

Search

Navigation